Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,406 matching trials from the live ClinicalTrials.gov search.
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
Encaleret, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
Conditions
Neonatal Abstinence Syndrome
Interventions
Phenobarbital, Clonidine
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
35 Weeks and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions
Magnesium sulfate, Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Healthy Subject, Overweight
Interventions
Glucosamine, Placebo
Dietary Supplement · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
20 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Interventions
Acetaminophen, Gabapentin, Orphenadrine, Lidocaine, Marcaine, Ketamine, Methadone, Tramadol, Ketorolac, Morphine Sulfate, Fentanyl, Dilaudid, Hydrocodone-Acetaminophen Tab 5-325 MG, HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
Drug
Lead sponsor
University of Illinois College of Medicine at Peoria
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, sodium lauryl sulfate, saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Floatation Experience in Nurses and Physicians

NCT05977894
Conditions
Burnout, Professional, Negative Affect, Positive Affect, Wellbeing, Burnout, Psychological
Interventions
Reduced Environmental Stimulation Therapy
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Youngstown, Ohio
Conditions
Pyruvate Kinase Deficiency
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Conditions
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Laboratory Biomarker Analysis, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more
Conditions
Migraine Headaches
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Trauma, Acute Pain
Interventions
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Migraine, Trigger Induced Migraine
Interventions
Rimegepant 75 MG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
92
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Conditions
Myopia
Interventions
Atropine Sulfate 0.05% Oph Soln, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
6 Years to 11 Years
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Berkeley, California • Fullerton, California + 10 more
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
Conditions
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Drug · Biological
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more
Conditions
Systemic Amyloidosis
Interventions
Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions
Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more
Conditions
Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Interventions
conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
138
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, lomustine, vincristine sulfate, adjuvant therapy, iodine I 131 monoclonal antibody 3F8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Conditions
High Grade Glioma, Glioblastoma, Gliosarcoma
Interventions
Dexbrompheniramine, Temozolomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska